- the Department of Emergency, the Affiliated Hospital of North Sichuan Medical College, Nanchong Sichuan 637000, China;
急性肺损伤(acute lung injury,ALI)是临床常见的呼吸系统急危重症,其发病机制复杂,病死率高。肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)是ALI发生、发展过程中非常重要的细胞因子。本文就TNF-α在ALI中的作用和以抗TNF-α为靶点治疗ALI的相关研究进行综述。
Citation: LI Mengqin,CAO Xiaoping.. TNF-α and Acute Lung Injury. West China Medical Journal, 2009, 24(7): 1896-1899. doi: Copy
1. | |
2. | |
3. | |
4. | SEMENZATO G. Tumor necrosis factor: a cytokine with multiple biological activities[J]. Br J Cancer,1990,61:354-361.. |
5. | 章敬波,林建银,杨恬.医学细胞分子生物学[M].第1版.北京:中国协和医科大学出版社,2002:6548-5494.. |
6. | 金惠铭,卢建,殷莲华.细胞分子病理生理学[M].第1版.郑州:郑州大学出版社,2002:173-174.. |
7. | 刘红菊,李元桂,毕爱华.肿瘤坏死因子在急性肺损伤发病机制中的作用[J].国外医学免疫分册,1996,(5):229-231.. |
8. | OKAJIMA K. Regulation of inflammatory responses by endothelial cellsunderstanding the molecular mechanism(s) and its therapeutic application to sepsis[J]. Masui,2008,57(3):311-20.. |
9. | VELDHUIZEN E J, HAAGSMAN H P. Role of pulmonary surfactant components in surface film formation and dynamics[J]. Biochim Biophys Acta,2000,1467(2):255-270.. |
10. | BERHANE K, MARGANA R K, BOGGARAM V. Characterization of rabbit SPB promoter region responsive to downregulation by tumor necrosis factoralpha[J]. Am J Physiol Lung Cell Mol Physiol,2000,279(5):L806-814.. |
11. | MIAKOTINA O L, SNYDER J M. TNFalpha inhibits SPA gene expression in lung epithelial cells via p38 MAPK[J]. Am J Physiol Lung Cell Mol Physiol,2002,283(2):L418-427.. |
12. | WILCOX P, MILLIKEN C, BRESSLER B. Highdose tumor necrosis factor alpha produces an impairment of hamster diaphragm contractility. Attenuation with a prostaglandin inhibitor[J]. Am J Respir Crit Care Med,1996,153(5):1611-1615.. |
13. | WILCOX P, OSBORNE S, BRESSLER B. Monocyte inflammatory mediators impair in vitro hamster diaphragm contractility[J]. Am Rev Respir Dis,1992,146(2):462-466.. |
14. | SHERIDAN B C, MCINTYRE R C, MELDRUM D R, et al. Pentoxifylline treatment attenuates pulmonary vasomotor dysfunction in acute lung injury[J]. J Surg Res,1997,71(2):150-154.. |
15. | MEDURI G U, KOHLER G, HEADLEY S, et al. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome[J]. Chest,1995,108(5):1303-1314.. |
16. | PARSONS P E, MATTHAY M A, WARE L B, et al. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol,2005,288(3):L426-431.. |
17. | VAN RIEMSDIJKVAN OVERBEEKE I C, BAAN C C, NIESTERS H G M, et al. The TNFalpha system in heart failure and after heart transplantation: plasma protein levels, mRNA expression, soluble receptors and plasma buffer capacity[J]. Eur Heart J,1999,20(11):833-840.. |
18. | BOYLE E M Jr, CANTY T G Jr, MORGAN E N, et al. Treating myocardial ischemiareperfsion injury by targeting endothelial cell transcription[J]. Ann Thorac Surg,1999,68(5):19491953.. |
19. | SATO Y, HIRAMATSU Y, HOMMA S, et al. Phosphodiesterase type 4 inhibitor rolipram inhibits actibation of monocytes during extracorporeal circulation[J]. J Thorac Cardiovasc Surg,2005,130(2):346-350.. |
20. | SOUZA D G, CASSALI G D, POOLE S, et al. Effects of inhibition of PDE4 and TNFα on local and remote injuries following ischaemia and reperfusion injury[J]. Br J Pharmacol,2001,134(5):985-994. doi: 10.1038/sj.bjp.0704336.. |
21. | MALAZDREWICH C, THUMBIKAT P, ABRAHAMSEN M S, et al. Pharmacological inhibition of Mannheimia haemolytica lipopolysaccharide and leukotoxininduced cytokine expression in bovine alveolar macrophages[J]. Microb Pathog,2004,36(3):159-169.. |
22. | RBE C E, WILFERT F, UTHE D, et al. Modulation of radiationinduced tumor necrosis factor α (TNF-α) expression in the lung tissue pentoxifylline[J]. Radiother Oncol,2002,64(2):177-187. |
23. | RUIZORTEGA M, LORENZO O, SUZUKI Y, et al. Proinflammatory actions of angiotensins[J]. Curr Opin Nephrol Hypertens,2001,10(3):321-329.. |
24. | YAO H W, MAO L G, ZHU J P. Protective effects of pravastatin in murine lipopolysaccharideinduced acue lung injury[J]. Clin Experiment Pharmacol Physiol,2006,33(9):793-797.. |
25. | GRIP O, JANCIAUSKIENE S, LINDGREN S. Pravastatin downregulates inflammatory mediators in human monocytes in vitro[J]. Eur J Pharmacol,2000,410(1):83-92.. |
26. | AMATO R J. Thalidomide: an antineoplastic agent[J]. Curr Oncol Rep,2002,4(1):56-62.. |
27. | MOREIRA A L, SAMPAIO E P, ZMUIDZINAS A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation[J]. J Exp Med,1993,177(6):1675-1680. doi: 10.1084/jem.177.6.16A75.. |
28. | ROCHA A C, FERNANDES E S, QUINTO N L, et al. Relevance of tumour necrosis factorα for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw[J]. Br J Pharmacol,2006,148(5):688-695.. |
29. | MUKHOPADHYAY S, HOIDAL J R, MUKHERJEE T K. Role of TNFα in pulmonary pathophysiology[J]. Respir Res,2006,7(1):125-127.. |
30. | GEARING A J, BECKETT P, CHRISTODOULOU M, et al. Processing of tumour necrosis factoralpha precursor by metalloproteinases[J]. Nature,1994,370(6490):555-557.. |
31. | CORBEL M, LANCHOU J, GERMAIN N, et al. Modulation of airway remodelingassociated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice[J]. Eur J Pharmacol,2001,426(1-2):113-121.. |
32. | EBERT E C. Infliximab and the TNFα system[J]. Am J Phisiol Gastrointest Liver Physiol,2009,296(3):G612-620.. |
33. | MUTLU G M, MUTLU E A, BELLMEYER A, et al. Pulmonary adverse events of antitumor necrosis factorα antibody therapy[J]. Am J Med,2006,119(8):639-646; Comment in: Am J Med,2007,120(12):e21; author reply e23.. |
- 1.
- 2.
- 3.
- 4. SEMENZATO G. Tumor necrosis factor: a cytokine with multiple biological activities[J]. Br J Cancer,1990,61:354-361..
- 5. 章敬波,林建银,杨恬.医学细胞分子生物学[M].第1版.北京:中国协和医科大学出版社,2002:6548-5494..
- 6. 金惠铭,卢建,殷莲华.细胞分子病理生理学[M].第1版.郑州:郑州大学出版社,2002:173-174..
- 7. 刘红菊,李元桂,毕爱华.肿瘤坏死因子在急性肺损伤发病机制中的作用[J].国外医学免疫分册,1996,(5):229-231..
- 8. OKAJIMA K. Regulation of inflammatory responses by endothelial cellsunderstanding the molecular mechanism(s) and its therapeutic application to sepsis[J]. Masui,2008,57(3):311-20..
- 9. VELDHUIZEN E J, HAAGSMAN H P. Role of pulmonary surfactant components in surface film formation and dynamics[J]. Biochim Biophys Acta,2000,1467(2):255-270..
- 10. BERHANE K, MARGANA R K, BOGGARAM V. Characterization of rabbit SPB promoter region responsive to downregulation by tumor necrosis factoralpha[J]. Am J Physiol Lung Cell Mol Physiol,2000,279(5):L806-814..
- 11. MIAKOTINA O L, SNYDER J M. TNFalpha inhibits SPA gene expression in lung epithelial cells via p38 MAPK[J]. Am J Physiol Lung Cell Mol Physiol,2002,283(2):L418-427..
- 12. WILCOX P, MILLIKEN C, BRESSLER B. Highdose tumor necrosis factor alpha produces an impairment of hamster diaphragm contractility. Attenuation with a prostaglandin inhibitor[J]. Am J Respir Crit Care Med,1996,153(5):1611-1615..
- 13. WILCOX P, OSBORNE S, BRESSLER B. Monocyte inflammatory mediators impair in vitro hamster diaphragm contractility[J]. Am Rev Respir Dis,1992,146(2):462-466..
- 14. SHERIDAN B C, MCINTYRE R C, MELDRUM D R, et al. Pentoxifylline treatment attenuates pulmonary vasomotor dysfunction in acute lung injury[J]. J Surg Res,1997,71(2):150-154..
- 15. MEDURI G U, KOHLER G, HEADLEY S, et al. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome[J]. Chest,1995,108(5):1303-1314..
- 16. PARSONS P E, MATTHAY M A, WARE L B, et al. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury[J]. Am J Physiol Lung Cell Mol Physiol,2005,288(3):L426-431..
- 17. VAN RIEMSDIJKVAN OVERBEEKE I C, BAAN C C, NIESTERS H G M, et al. The TNFalpha system in heart failure and after heart transplantation: plasma protein levels, mRNA expression, soluble receptors and plasma buffer capacity[J]. Eur Heart J,1999,20(11):833-840..
- 18. BOYLE E M Jr, CANTY T G Jr, MORGAN E N, et al. Treating myocardial ischemiareperfsion injury by targeting endothelial cell transcription[J]. Ann Thorac Surg,1999,68(5):19491953..
- 19. SATO Y, HIRAMATSU Y, HOMMA S, et al. Phosphodiesterase type 4 inhibitor rolipram inhibits actibation of monocytes during extracorporeal circulation[J]. J Thorac Cardiovasc Surg,2005,130(2):346-350..
- 20. SOUZA D G, CASSALI G D, POOLE S, et al. Effects of inhibition of PDE4 and TNFα on local and remote injuries following ischaemia and reperfusion injury[J]. Br J Pharmacol,2001,134(5):985-994. doi: 10.1038/sj.bjp.0704336..
- 21. MALAZDREWICH C, THUMBIKAT P, ABRAHAMSEN M S, et al. Pharmacological inhibition of Mannheimia haemolytica lipopolysaccharide and leukotoxininduced cytokine expression in bovine alveolar macrophages[J]. Microb Pathog,2004,36(3):159-169..
- 22. RBE C E, WILFERT F, UTHE D, et al. Modulation of radiationinduced tumor necrosis factor α (TNF-α) expression in the lung tissue pentoxifylline[J]. Radiother Oncol,2002,64(2):177-187.
- 23. RUIZORTEGA M, LORENZO O, SUZUKI Y, et al. Proinflammatory actions of angiotensins[J]. Curr Opin Nephrol Hypertens,2001,10(3):321-329..
- 24. YAO H W, MAO L G, ZHU J P. Protective effects of pravastatin in murine lipopolysaccharideinduced acue lung injury[J]. Clin Experiment Pharmacol Physiol,2006,33(9):793-797..
- 25. GRIP O, JANCIAUSKIENE S, LINDGREN S. Pravastatin downregulates inflammatory mediators in human monocytes in vitro[J]. Eur J Pharmacol,2000,410(1):83-92..
- 26. AMATO R J. Thalidomide: an antineoplastic agent[J]. Curr Oncol Rep,2002,4(1):56-62..
- 27. MOREIRA A L, SAMPAIO E P, ZMUIDZINAS A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation[J]. J Exp Med,1993,177(6):1675-1680. doi: 10.1084/jem.177.6.16A75..
- 28. ROCHA A C, FERNANDES E S, QUINTO N L, et al. Relevance of tumour necrosis factorα for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw[J]. Br J Pharmacol,2006,148(5):688-695..
- 29. MUKHOPADHYAY S, HOIDAL J R, MUKHERJEE T K. Role of TNFα in pulmonary pathophysiology[J]. Respir Res,2006,7(1):125-127..
- 30. GEARING A J, BECKETT P, CHRISTODOULOU M, et al. Processing of tumour necrosis factoralpha precursor by metalloproteinases[J]. Nature,1994,370(6490):555-557..
- 31. CORBEL M, LANCHOU J, GERMAIN N, et al. Modulation of airway remodelingassociated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice[J]. Eur J Pharmacol,2001,426(1-2):113-121..
- 32. EBERT E C. Infliximab and the TNFα system[J]. Am J Phisiol Gastrointest Liver Physiol,2009,296(3):G612-620..
- 33. MUTLU G M, MUTLU E A, BELLMEYER A, et al. Pulmonary adverse events of antitumor necrosis factorα antibody therapy[J]. Am J Med,2006,119(8):639-646; Comment in: Am J Med,2007,120(12):e21; author reply e23..